Results for eritrocitih translation from Slovenian to English

povprečna količina hemoglobina v eritrocitih
mean corpuscular haemoglobin

povprečna koncentracija hemoglobina v eritrocitih (mchc)
mean corpuscular haemoglobin concentration (mchc)

mutagenost – test mikronukleusov v eritrocitih sesalcev in vivo
mutagenicity — in vivo mammalian erythrocyte micronucleus test

mutagenost — preizkus mikronukleusov v eritrocitih sesalcev in vivo
mutagenicity - in vivo mammalian erythrocyte micronucleus test

pri tem so merili aktivnost ca v eritrocitih, da bi ugotovili stopnjo sistemske zavore ca.
in an oral pharmacokinetic study, healthy volunteers received 1 mg capsules of brinzolamide twice daily for up to 32 weeks and rbc ca activity was measured to assess the degree of systemic ca inhibition.

do 4. tedna zdravljenja je koncentracija brinzolamida v eritrocitih dosegla raven med približno 20 in 40 m.
brinzolamide rbc concentration ranged from about 20 to 40 µm by week 4 of treatment.

hidroklorotiazid se poleg tega kopiči v eritrocitih v približno 3-krat večji koncentraciji kot v plazmi.
hydrochlorothiazide also accumulates in erythrocytes at approximately 3 times the level in plasma.

antigen so odkrili tudi na majhnem odstotku (< 5 %) granulocitov, ne pa na eritrocitih ali trombocitih.
the antigen has been found on a small percentage (< 5%) of granulocytes, but not on erythrocytes or platelets.

negativni rezultati pomenijo, da preizkušana snov pri preizkusnih pogojih ne povzroča nastanka mikronukelusov v nezrelih eritrocitih preizkusne vrste.
negative results indicate that, under the test conditions, the test substance does not produce micronuclei in the immature erythrocytes of the test species.

kadar se živali tretirajo nepretrgano štiri tedne ali več, se lahko določi tudi incidenca mikronukleusov v vsaj 2000 zrelih eritrocitih na žival.
when animals are treated continuously for four weeks or more, at least 2000 mature erythrocytes per animal can also be scored for the incidence of micronuclei.

pri uporabi komercialnih oblik fosaprepitanta v koncentraciji do 1 mg/ml hemolize v polni človeški krvi ali pri izpranih eritrocitih niso opazili.
no hemolysis was found with the commercial formulation up to a fosaprepitant concentration of 1 mg/ml in human whole blood and washed human erythrocytes.

hidroksikarbamid se hitro porazdeli po telesu, vstopa v cerebrospinalno tekočino, se pojavi v peritonealni tekočini in ascitesu ter se zbira v levkocitih in eritrocitih.
hydroxycarbamide distributes rapidly throughout the human body, enters the cerebrospinal fluid, appears in peritoneal fluid and ascites, and concentrates in leukocytes and erythrocytes.

glavni presnovek brinzolamida pri človeku je n-desetilbrinzolamid, ki se tudi veže na ca-i v prisotnosti brinzolamida in se kopiči v eritrocitih.
n-desethyl brinzolamide is a major metabolite of brinzolamide formed in humans, which also binds to ca-i in the presence of brinzolamide and accumulates in rbcs.

razmerje koncentracij ribavirina v polni krvi proti plazmi je približno 60 proti 1; prebitek ribavirina v polni krvi pa je v obliki ribavirinskih nukleotidov, sekvestriranih v eritrocitih.
the ratio of whole blood:plasma ribavirin concentrations is approximately 60:1; the excess of ribavirin in whole blood exists as ribavirin nucleotides sequestered in erythrocytes.

v stanju dinamičnega ravnovesja se je koncentracija brinzolamida in njegovega presnovka v eritrocitih gibala med 22,0 in 46,1 za brinzolamid ter med 17,1 in 88,6 m za presnovek.
at steady-state, brinzolamide and its metabolite rbc concentrations ranged from 22.0 to 46.1 and 17.1 to 88.6 µm, respectively.

zaradi velike afinitete za ca- ii se v veliki meri porazdeli v eritrocitih in ima v polni krvi dolgo razpolovno dobo (srednja vrednost približno 24 tednov).
due to its high affinity for ca-ii, brinzolamide distributes extensively into the rbcs and exhibits a long halflife in whole blood (mean of approximately 24 weeks).

z zmanjšanjem očistka kreatinina se je koncentracija n-desetilbrinzolamida v eritrocitih povečala in celotna aktivnost ca v eritrocitih zmanjšala, toda eritrocitna koncentracija brinzolamida in aktivnost ca-ii sta ostali nespremenjeni.
n-desethylbrinzolamide rbc concentrations increased and total rbc ca activity decreased with decreasing creatinine clearance but brinzolamide rbc concentrations and ca-ii activity remained unchanged.

drugi znani farmakološki učinki hidroksikarbamida, ki utegnejo prispevati k njegovim koristnim učinkom pri srpasto celičnem sindromu, vključujejo znižanje števila nevtrofilnih levkocitov, zvišanje vsebnosti vode v eritrocitih, zvišanje deformabilnosti srpastih celic in spremenjeno adhezijo rdečih krvničk na endotel.
other known pharmacological effects of hydroxycarbamide which may contribute to its beneficial effects in sickle cell syndrome include decrease of neutrophils, increase of the water content of erythrocytes, increase of the deformability of sickled cells, and altered adhesion of red blood cells to the endothelium.

drugi kazalniki so opisani, na primer prisotnost svinca v urinu, dejavnost alad v eritrocitih, delta-aminolevulinska kislina, ravni kopropor -rina v urinu in celo koncentracija svinca v laseh. prednosti in pomanjkljivosti takšnih preskusov bodo odvisne od posameznih okoliščin izpostavljenosti.
& or฀ the฀ purposes฀ of฀$irective฀ %# ฀ and฀ therefore฀ for฀ the฀ purposes฀ of฀this฀ guide฀ health฀ surveillance฀ means฀ @the฀ assessment฀ of฀ an฀ individual฀ worker฀ to฀determine฀ the฀ state฀ of฀ health฀ of฀ that฀ individual฀ as฀ related฀ to฀exposure฀ to฀ specilc chemical agents at work฀ !rticle ฀ f